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1. INTRODUCTION-  
Currently, Nasal drug delivery has been recognized as a 
very promising route for delivery of therapeutic 
compounds including biopharmaceuticals
1
. Nasal 
administration is a logical choice for topical nasal 
treatments such as antihistamines and corticosteroids. The 
nasal mucosa has also received attention as a viable means 
of systemic administration of analgesics, sedatives, 
hormones, cardiovascular drugs, and vaccines. 
2
 
Conventionally, the nasal route has been used for local 
delivery of drugs for treating nasal allergy, nasal 
congestion, or nasal infections. However systemic delivery  
through the nasal route has recently begun to explore 
possibilit ies for those requiring a rapid onset of action or 
necessitating avoidance of severe proteolysis involved in 
oral administration (e.g., most peptide and protein drugs). 
Successful attempts to deliver corticosteroid hormones 
through the nasal route for systemic absorption
3
 have 
triggered further studies in this area. 
 The anatomy and physiology of the nasal passage indicate 
that nasal administration has potential practical advantages 
for the introduction of therapeutic drugs into the systemic 
circulat ion. The concentration-time profiles achieved after 
nasal administration are often similar to those after 
intravenous admin istration, resulting in a rapid onset of 
pharmacological activity
4
.  Bjerre et al. showed that the 
sedative propiomazine, fo r which a rapid onset of action is 
desirable. and it absorbed within 5 minutes after nasal 
administration to rats. 
5
 Drugs ranging from s mall 
chemicals to large macromolecules including 
peptide/protein therapeutics, hormones, and vaccines, are 
being delivered through the nasal cavity. Marketed 
products include a range of antimigraine drugs 
(e.g.,sumatriptan, zo lmitriptan, ergotamine, and 
butorphanol) as well as some peptides  (e.g.,calcitonin, 
desmopressin, and buserelin ).
6
 Later the use of the nasal 
route for delivery of vaccines, especially against 
respiratory infections such as influenza, is attracting 
interest from vaccine delivery scientists.
7
 
Currently, nasal admin istration is used therapeutically for 
the systemic absorption of drugs in a variety of indications, 
including sumatriptan for migraine
8
, the antidiuretic 
desmopressin for the treatment of diabetes insipidus
9
 and 
oxytocin fo r secretion of milk in response to suckling 
during breast feeding or contraction of the uterine muscle 
to hasten childbirth by nasal delivery. Other drugs still in  
the research and development pipeline, which have 
potential for admin istration nasally, include vitamin B12,
10
 
various benzodiazepines
11-12 
and the dopamine agonist 
apomorphine for patients with Parkinsonism.
13
 Nicotine is 
also available in a nasal dosage form for use in assisting 
smoking cessation 
1.1Advantages of Nasal Drug Delivery Systems 
14-15
 
a) Large nasal mucosal surface area for dose 
absorption 
b) Rapid drug absorption via highly vascularized  
mucosa 
c) Rapid onset of action 
d) Ease of administration, noninvasive 
e) By pass the BBB 
f) Avoidance of the gastrointestinal tract and first pass 
metabolism 
g) Improved bioavailability 
h) Direct transport into systemic circulation and CNS 
is possible 
i) Lower dose/reduced side effects 
j) Improved convenience and compliance 
k) Self-administration 
1.2 Limitations-  
a) Volume that can be delivered into nasal cavity is 
restricted to 25-200 μl. 
b) Not feasible for high molecular weight more than 1k 
Da 
c) Adversely affected by pathological conditions 
d) Drug permeability may alter due to ciliary 
movement 
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e) Drug permeability is limited due to enzymatic 
inhibit ion  
f) Nasal irritants drugs cannot be administered  
through this route 
g) Exact mechanism is not yet clearly known  
2. ANATOMY AND PHYS IOLOGY OF NOS E  
The human nose is divided by the median septum, a central 
partition of bone and cartilage; each symmetrical half 
opens at the face via the nostrils and connects with the 
mouth at the nasopharynx. The nasal vestibule, the 
respiratory region and the olfactory region are the three 
main reg ions of the nasal cavity.
16 
The lateral walls of the 
nasal cavity include a folded structure which enlarges the 
surface area in the nose to about 150 cm2.
17
 This folded 
structure includes three turbinates. The superior, the 
median and the inferior . In the main nasal airway, the 
passages are narrow, normally only 1–3 mm wide and this 
narrow structure enables the nose to carry out its main  
functions.
18
 During inspiration, the air comes into close 
contact with the nasal mucosa and particles such as dust 
and bacteria are trapped in the mucus. Additionally, the 
inhaled air is warmed and moistened as it passes over the 
mucosa. This conditioning of the inhaled air is facilitated 
by the fluid secreted by the mucosa and the high blood 
supply in the nasal epithelium. 
17-18
 
 
Figure 1: Anatomy of the nose (To the right is a cross-section of the nose) 
The sub mucosal zone of the nasal passage is extremely  
vascular and this network of veins drains blood from the 
nasal mucosa directly to the systemic circulat ion, thus 
avoiding first-pass metabolis m
19
 the nasal cavity is 
covered with a mucous membrane which can be div ided 
into non-olfactory and olfactory epithelium areas. The 
non-olfactory area includes the nasal vestibule, which is 
lined with skin-like cells and respiratory region.  
2.1 The Res piratory Region 
20-25
 
The respiratory epithelium is composed of four types of 
cells, namely, non-ciliated and ciliated columnar cells, 
basal cells and goblet cells. These cells facilitate active 
transport processes such as the exchange of water and ions 
between cells and motility of cilia (where applicable). 
They may also serve to prevent drying of the mucosa by 
trapping moisture.
 
 
Figure 2: Respiratory epithelium of the nasal cavity, showing the four main types of cells  
About 15–20% of the respiratory cells are covered with a 
layer of long cilia, which move in a coordinated way to 
propel mucus towards the pharynx. Mucus (or nasal 
secretion) is a complex mixture of materials ,consisting of 
approximately 95% water, 2% mucin, 1% salts, 1% of 
other proteins such as albumin, immunoglobulins, 
lysozymes and lactoferrin and <1% lipids (Kaliner et al., 
1984). Mucus is present in two layers on the epithelium in  
order to facilitate mucociliary clearance. A viscous gel 
layer, the ‘mucus blanket’ (Fig. 3c; ‘gel layer’, 2–4 mm 
thickness) floats on the serous fluid layer (Fig. 3e ‘sol 
layer’, 3–5 mm thickness). The viscous gel layer is moved 
along by the hook shaped cilia termin i during the energy 
dependent ‘effective stroke’ phase of the ciliary mot ion 
(Fig. 3).  
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Figure 3: The relationship between ciliary mot ion and mucus layer composition that allows   mucociliary clearance. (a) 
Effective Stroke, (B) Recovery Stroke, (C) Gel Layer, (D) Direction of Gel Layer Movement,  (E) Sol Layer.  
Cilia are up to 7mm in length when fully extended but can 
fold to half this length during the recovery stroke where 
the hook terminus detaches from the gel layer and moves 
immersed in the sol layer in the opposite direction to the 
gel layer movement (Fig. 3b). The cilia beat with a 
frequency of 1000 strokes per min. Hence the mucus 
moves only in one direction from the anterior to the 
posterior part of the nasal cavity to the nasopharynx 
2.2 The Olfactory Region [20-25] 
In human, the olfactory region is located on the roof of the 
nasal cavities, just below the cribriform p late of the 
ethmoid bone, which separates the nasal cavities from the 
cranial Cavity. The o lfactory tissue is often yellow in  
color, in contrast to the surrounding pink tissue. Humans 
have relatively simple noses, since the primary function is 
breathing, while other mammals have more complex noses 
better adapted for the function of olfaction.
24
 The olfactory 
epithelial layer predominantly contains three cell types: the 
olfactory neural cells, the subtentacular (also known as 
supporting) cells and the basal cells. Basal cells are 
progenitor cells (of supporting cells) that also provide 
mechanical support via anchorage to other cells.(Fig-4) 
 
Figure 4: Anatomical connections between the olfactory mucosa in the nose and the CSF in the subarachnoid space 
outside the olfactory bulb. 
The olfactory epithelium is a gateway for substance 
entering the CNS and peripheral circulation. The neuronal 
connection between the nasal mucosa and brain provide a 
unique pathway for the non-invasive delivery of 
therapeutic agents to CNS. The olfactory neuronal 
pathway provides both intraneuronal an extraneuronal 
pathway into the brain. The intraneuronal pathway 
involves axonal transport and require to hours to days for 
drugs to reach different brain regions.While the 
extraneuronal pathway probably relies on the bulk flow 
transport through perineural channels, which delivers 
drugs directly to the brain parenchymal tissue or CSF.The 
extraneuronal pathway allows therapeutic agents to reach 
the CNS within minutes. 
Thorne et al.
25
 have reported that the trigeminal neural 
pathway may also be involved in rapidly delivering protein 
therapeutic agents, such as insulin like growth factor-1 to 
brain and spinal cord following intranasal admin istration . 
The transport of drugs across the nasal membrane and into 
the bloodstream may involve either passive diffusion of 
drug molecules through the pores in nasal mucosa, 
Including blood supply , nerve supply or some form of non 
passive transport. 
3. BARRIERS  FOR NASAL DRUG DELIVERY 
3.1 Low bioavailability  
Bioavailability of polar drugs is generally low, about 10% 
for low molecular weight drugs and not above 1% for 
peptides such as calcitonin and insulin.
26
 The most 
important factor limiting the nasal absorption of polar 
drugs and especially large molecu lar weight polar drugs 
such as peptides and proteins are the low membrane 
permeability. Drugs can cross the epithelial cell membrane 
either by the transcellular route exploit ing simple 
concentration gradients by the receptor mediated or 
vesicular transport mechanisms or by the paracellu lar route 
Singh et al                              Journal of Drug Delivery & Therapeutics; 2012, 2(3): 22-33    25 
© 2011, JDDT. All Rights Reserved                                     ISSN: 2250-1177                                      CODEN: JDDTAO 
through the tight junctions between the cells. Polar drugs 
with molecular weights below 1000 Da will generally pass 
the membrane using the latter route.
27
 Although tight 
junctions are dynamic structures and can open and close to 
a certain degree when needed, the mean size of these 
channels is of the order of less than 10 Å and the transport 
of larger molecules is  considerably more limited. Larger 
peptides and proteins are able to pass the nasal membrane 
using an endocytotic transport process but only in low 
amounts.
28
 Nasal absorption of such polar drugs can be 
greatly improved by co administration of absorption 
enhancing agents.
29
 Agents generally used for transnasal 
absorption includes surfactants (laureth-9, sodium 
laurylsulfate), bile salts ,bile salt derivatives (sodium 
glycocholate, sodium deoxycholate, sodium 
taurodihydrofusidate), fatty acids,fatty acid derivatives 
(linoleic acid), phospholipids (lysophosphatidylcholine), 
various cyclodextrins and cationic compounds like 
chitosan and its derivatives, poly-L-arg inine, poly-L-
lysine.
30
 These enhancers work by a variety of mechanis ms 
but generally they act by altering the permeability of the 
epithelial cell layer by modifying the phospholipid  
bilayers, leaching of proteins from the membrane or even 
stripping off the outer layer of the mucosa. Some of these 
enhancers also have an effect on the tight junctions and /or 
work as enzymat ic degradation inhibitors. With such 
absorption enhancing agents, increased bioavailability was 
obtained, even for larger peptides such as insulin. In  
animal studies it has been shown for a range of enhancing 
agents that there is a direct correlation between the 
absorption enhancing effect and the damage to the nasal 
mucosa.
31
 This is particularly true for bile salts and 
surfactants. For other enhancers, such as cyclodextrins and 
chitosan  the enhancing effect outweighs the damage 
caused to the mucosa. Hence, it is of great importance to 
consider the choice of absorption enhancer for a nasally 
delivered drug that is not easily absorbed, especially in  
terms of potential nasal and systemic toxicity.  
3.2 Mucociliary clearance  
The general fast clearance of the administered formulat ion 
from the nasal cavity due to the mucociliary clearance 
mechanis m is another factor of importance for low 
membrane transport. This is especially the case when the 
drug is not absorbed rapidly enough across the nasal 
mucosa. It has been shown that for both liquid and powder 
formulat ions, which are not bioadhesive, the half life for 
clearance is of the order of 15 - 30 min.
32,33
 The use of 
bioadhesive excipients in the formulat ions is an approach 
to overcome the rapid mucociliary clearance. The 
clearance may also be reduced by depositing the 
formulat ion in the anterior, less ciliated part of the nasal 
cavity thus leading to improved absorption.
34,35
 
3.3 Enzymatic Degradation- 
Another contributing, but often less considered factor to 
the low bioavailability of peptides and proteins across the 
nasal mucosa is the possibility of an enzymatic 
degradation of the molecule in the lumen of the nasal 
cavity or during passage through the epithelial barrier. 
These sites both contain exo-peptidases such as mono and 
diaminopeptidases that can cleave peptides at their N and 
C terminals and endo-peptidases such as serine and 
cysteine, which can attack internal peptide bonds .
36
 The 
use of enzyme inhibitor may be approaches to overcome 
this barrier.
37
 In summary, the nose offers unique 
advantages as admin istration site for drug delivery. 
However, low permeability fo r polar and high molecu lar 
weight drugs, rapid clearance of the delivery system from 
the cavity and possible enzymatic degradation of the drug 
in the nose may be encountered. These challenges can be 
faced by various approaches, such as use of bio-adhesive 
systems and absorption enhancers. 
4. MECHANIS M OF DRUG ABSORPTION 
THROUGH NOS E 
The first step in the absorption of drug from the nasal 
cavity is passage through the mucus . Small unchanged 
particles easily pass through this layer. However, large or 
charged particles may find it more d ifficu lt to cross. 
Subsequent to a drug’s passage through the mucus, there 
are several mechanisms for absorption through the 
mucosa. These include transcellular or simple diffusion 
across the membrane, paracellular transport via movement 
between cell and transcytosis by vesicle carriers .
33
 
Obstacles to drug absorption are potential metabolis m 
before reaching the systemic circulat ion and limited 
residence time in the cavity. Several mechanis ms have 
been proposed but the following two mechanisms have 
been considered predominantly.  
 The first mechanism involves an aqueous route of 
transport, which is also known as the paracellular 
route. This route is slow and passive. There is an 
inverse log-log correlation between intranasal 
absorption and the molecular weight of water-soluble 
compounds. Poor bio-availab ility was observed for 
drugs with a molecular weight greater than 1000 
Daltons.
38
 
 The second mechanism involves transport through a 
lipoidal route that is also known as the transcellular 
process and is responsible for the transport of 
lipophilic drugs that show a rate dependency on their 
lipophilicity. Drugs also cross cell membranes by an 
active transport route via carrier-mediated means or 
transport through the opening of tight junctions.
38
 For 
example, Chitosan, a natural biopolymer opens tight 
junctions between epithelial cells to facilitate drug 
transport.
39
 
5. CRUCIAL FACTORS FOR NASAL 
FORMULATIONS 
40
 
The deposition of drug and deposition area is mainly  
dependant on the delivery system and the delivery device 
because of nasal cavity has the peculiar anatomy and 
physiology. The deposition is influenced by factors such as 
mode of admin istration, particle size of the formulation, 
velocity of the delivered particles, spray angle and cone. A 
wider spray cone could result in loss of the formulat ion 
while narrower spray cones would lead to limited 
deposition with respect to the available absorption surface 
area. An optimal spray cone may effectively  and rapidly  
deliver the drug from the formulation at desired specific 
site/s present within nasal cavity. The selection of delivery 
system depends upon the drug used, therapeutic indication, 
patient population, and last but not least, market ing 
preferences. In addition to dosage form design, 
pharmacokinetics and bioavailability of drugs may be 
governed by several factors following intranasal 
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administration. Some of the physicochemical, formulation, 
and physiological factors must be considered prior to 
designing an intranasal delivery system for CNS targeting.  
PHYS ICOCHEMICAL PROPERTIES  OF DRUGS - 
Physicochemical properties are one of the important 
aspects in design of nasal formulat ion 
6. FACTORS RELATED TO DRUG  
6.1 Lipophilicity 
Absorption of drug substance through biological 
membrane may be dependent on hydrophilic lipophilic 
balance of the compound.
41
 On increasing lipophilicity, the 
nasal absoption of the compound normally increases .
42
 
Although In one study it was found that lipophilic 
compounds alprenolol and propranolol were well absorbed 
from the nasal mucosa, in comparision to the hydrophilic 
drug metoprolol. Lipophilic compounds tend to readily 
cross biological membranes via the transcellular route 
since they are able to partition into the lip id (b ilayer) of the 
cell membrane and diffuse into and traverse the cell in the 
cell cytoplasm.Nasal absorption of steroids was directly 
correlated with lipophillicity of drug molecules and was 
found to be independent of pH.
43
 A number of lipophilic 
drugs such as naloxone, buprenorphine, testosterone
44 
and 
17a-ethinyloestradiol,
45
 have been shown to be completely  
or almost completely absorbed nasally in an imal models.  
6.2 Partition Coefficient and pKa 
According to the pH partition theory, unionized form of 
drug are well absorbed compared with ionized form of 
drug and the same theory is applicable in the case of nasal 
drug absorption. Jiang et al.
46
 conducted a study to 
determine the quantitative relationship between the 
physicochemical properties of drugs and their nasal 
absorption, using diltiazem hydrochloride and paracetamol 
as model drugs. The results showed that a quantitative 
relationship existed between the partition coefficient and 
the nasal absorption constant. 
6.3 Chemical form 
The chemical form of a drug is important in determin ing 
absorption. For example, conversion of the drug into a salt 
or ester form can alter its absorption. Huang et al.
47
 
reported that in-situ nasal absorption of carboxylic acid  
esters of L-tyrosine was significantly greater than that of 
unmodified L-tyrosine.  
6.4 Molecular weight 
A linear inverse correlation has been reported between the 
absorption of drugs and molecular weight up to 300 
Daltons. Absorption decreases significantly if the 
molecular weight is greater than 1,000 Daltons except with 
the use of absorption enhancers Based on the reports by 
Fisher et al.
48 
and Yamamto et al.
49
 it can be concluded that 
the permeat ion of drugs less than 300 Da is not 
significantly influenced by the physicochemical properties 
of the drug like molecu lar weight, s ize, formulation pH, 
pKa of molecule,, which will mostly permeate through 
aqueous channels of the biological membrane. 
6.5 Particle size 
It has been reported that particles greater than 10 µm in  
size are deposited in the nasal cavity. Particles that are 2 to 
10 µm can be retained in the lungs, and particles of less 
than 1 µm are exhaled. 
6.6 Solubility and dissolution rate  
Drug solubility and dissolution rates are important 
biopharmaceutical factors
50
 in determining nasal 
absorption from powders and suspensions. The particles 
deposited in the nasal cavity need to dissolve prior to 
absorption. Solubility of a drug or dosage form is the first 
prerequisite for absorption and bioavailib ility of dosage 
form. The fluid available for dissolution of drug particles  
in nasal cavity or mucosa is very less when compared to 
the gastrointestinal fluid in oral drug delivery.
51
 saturation 
solubility of drug in a given nasal physiological pH is very 
important parameter, which determines the rate and extent 
absorption of nasal dosage form. 
7. FORMULATION FACTORS  
7.1 pH of formulation  
Both the pH of the nasal cavity and pKa of a particular 
drug need to be considered to rationalize systemic 
absorption. Nasal irritat ion is minimized when products 
are delivered with a pH ranging between 4.5 and 6.5.
52
 
Lysozyme is found in nasal secretions, which is 
responsible for destroying certain bacteria at acidic pH.
53
 
Under alkaline conditions, lysozyme is inactivated and the 
nasal tissue is susceptible to microbial in fection. It is 
therefore advisable to keep the formulation at a pH of 4.5 
to 6.5 keeping in mind the physicochemical properties of 
the drug that absorbed in the un-ionized form. The delivery  
volume is limited by the size of the nasal cavity. An upper 
limit o f 25 mg/dose and a volume of 0.1-0.2 ml/nostril 
have been suggested.  
The pH of a nasal formulation is important for the 
following reasons: 
 To avoid irritation of nasal mucosa 
 To allow the drug to be available in unionized form 
for absorption 
 To prevent growth of pathogenic bacteria in the nasal 
passage 
 To maintain functionality of excipients such as 
preservatives 
 To sustain normal physiological ciliary movement  
7.2 Osmolarity 
Drug absorption can be affected  by tonicity of the  
formulat ion. Ohwaki et al.
43
  studied the effect of 
osmolarity on the absorption of secretin in rats and found 
that absorption reached a maximum at a sodium ch loride 
concentration of 0.462 M, because shrinkage of the nasal 
epithelial mucosa was observed at in the presence of 
hypertonic solutions.
54 
Hypertonic saline solutions are also 
known to inhib it or cease ciliary activity. Low pH has a 
similar effect on cells as hypertonic solutions.  
7.3 Gelling agents  
Retention of the nasal formulation in the nasal cavity can 
enhance therapeutic effect by virtue of enhancing rate and 
extent of drug absorption. According to a study by 
pennington et al.
55
 increasing the viscosity may provide a 
means of prolonging the effect of nasal formulation. 
Suzuki, et al.
56
  showed that a drug carrier, hydroxyl-
propylcellulose was effective for improving the absorption 
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of low molecu lar weight drugs but did not produce the 
same effect for h igh molecular weight peptides. 
7.4 Solubilizers 
The aqueous solubility of a drug is always a limitation for 
nasal drug delivery in solution. Conventional solvents or 
co-solvents such as glycols, small quantities of alcohol, 
Transcutol (diethylene glycol monoethyl ether), medium 
chain glycerides and Labrasol (saturated polyglycolyzed 
C8-C10 glyceride) can be used to enhance the solubility of 
drugs. Other options include the use of surfactants or 
cyclodextrins such as hydroxypropyl-beta-cyclodextrin  
that serve as biocompatible solubilizers and stabilizers in  
combination with lipophilic absorption enhancers. In such 
cases, impact of the solubilizers on nasal irritancy should 
be considered. 
7.5 Drug concentration, required dose, and dose 
volume 
Drug concentration, dose and volume of administration are 
three interrelated parameters that impact the performance 
of the nasal delivery system. Ex vivo experiments in rats 
demonstrated the effect of drug concentration on nasal 
drug absorption. Nasal absorption of I-tyrosyl-L-tyrosine 
was found to increase with increasing concentration of 
drug. However few experiments showed different effects 
of drug concentration on the absorption of drugs, for 
example the absorption of aminopyrine from rat nasal 
mucosa was constant as a function of its concentration.
57 
Interestingly, nasal absorption of salicylic acid was 
decreased with increasing concentration of administered 
drug and low absorption of high concentration of salicylic 
acid was lined with its nasal epithelial toxicity and nasal 
membrane resistance.
58
   
8. ROLE OF ABSORPTION ENHANCERS  
The selection of absorption enhancers is based upon their 
acceptability by regulatory agencies and their impact on 
nasal physiological function. Absorption enhancers may be 
required when a drug exh ibits poor membrane 
permeability, large molecular size, lack o f lipophilicity and 
susceptibility to enzymat ic degradation by 
aminopeptidases. 
Generally, the absorption enhancers act via one of the 
following mechanisms:  
 Inhibit enzyme activity  
 Reduce mucus viscosity or elasticity  
 Decrease mucociliary clearance  
 Open tight junctions; and  
 Solubilize o r stabilize the drug 
Absorption enhancers are generally classified as physical 
and chemical enhancers. Chemical enhancers act by 
destructing the nasal mucosa very often in an irreversible 
way, whereas physical enhancers affect nasal clearance 
reversibly by forming a gel. The enhancing effect 
continues until the gel is swallowed. Examples of chemical 
enhancers are chelating agents, fatty acids, bile acid salts, 
surfactants, and preservatives. Osmolarity and pH may  
accelerate the enhancing effect.
48
 
9. PHYS IOLOGICAL FACTORS  
9.1 Effect of deposition on absorption 
Deposition of the formulation in the anterior portion of the 
nose provides a longer nasal residence time and better 
absorption.
59
 The dosage form deposited in posterior 
chamber of nasal cavity will be eliminated by nasal 
mucocilliary clearance and hence show low bioavailability. 
The site of deposition and deposition pattern of liquid  
dosage form is dependent on the delivery device, mode of 
administration, physicochemical properties of drug 
molecule.
60
  
Harris
61 
compared the deposition and removal of metered  
dose sprays with nasal drops. Nasal sprays were deposited 
anteriorly, after which small portions were cleared slowly 
into nasal pharynx by mucociliary clearance. In contrast, 
drops were deposited mostly posteriorly and were removed 
rapidly in large portions into the nasal pharynx.  
9.2 Nasal blood flow 
The nasal mucosal membrane is very rich in vasculature 
and plays a vital role in the thermal regulat ion and 
humid ification of inhaled air.
18,19 
Drug absorption will 
depend upon the vasoconstriction and vasodilatation of 
these blood vessels. 
24
 
9.3 Effect of mucociliary clearance  
It is important that the integrity of the nasal clearance 
mechanis m is maintained to perform normal physiological 
functions such as the removal o f dust, allergens and 
bacteria. The absorption of drugs is influenced by the 
residence time between the drug and the epithelial t issue. 
The mucociliary clearance is inversely related to the 
residence time and therefore inversely proportional to the 
absorption of drugs administered. A prolonged residence 
time in the nasal cavity may also be achieved by using 
bioadhesive polymers,
34
 microspheres, chitosan, and 
polycarbophil, or by increasing the viscosity of the 
formulat ion. 
9.4 Effect of enzymatic activi ty 
Several enzymes that are present in the nasal mucosa 
might affect the stability of drugs. For example, proteins 
and peptides are subjected to degradation by proteases and 
amino-peptidase at the mucosal membrane.
37
  
9.5 Effect of pathological condition  
Intranasal pathologies such as  allergic rh initis, infections, 
or previous nasal surgery may affect the nasal mucociliary  
transport process and/or capacity for nasal absorption. 
During the common cold, the efficiency of an intranasal 
medication is often compromised. Nasal clearance is also 
reduced in insulin-dependent diabetes. Nasal pathology 
can also alter mucosal pH and thus affect absorption of 
drugs. An increased level of albumin and plasma proteins 
in nasal fluid was found in allerg ic rhin itis .
62 
However in 
recent study by Person [63] and coworkers has clearly 
shown that intranasal absorption of macromolecules is not 
increased allergic rhinit is. However introduction of nasal 
dosage form as an external stimulus increases the nasal 
mucus secretion and leads to drainage dosage forms and 
hence reduced bioavailability.
64
 
10. NASAL FORMULATIONS  
The deposition and deposition area are mainly a function 
of the delivery system and delivery  device. Different 
dosage forms and their application to deliver the drugs to 
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the central nervous system fo llowing intranasal drug 
delivery are discussed in this section. 
10.1 LIQUID DOSAGE FORMS  
Liquid dosage forms either in form of soluble, suspended 
or collo idal systems are normally used for formulat ing 
nasal delivery systems. 
10.1.1Nasal drops  
Nasal drops are one of the most simple and convenient 
delivery systems among all formulations. The main  
disadvantage of this system is the lack of dose precision.
65
 
It has been reported that nasal drops deposit human serum 
albumin in the nostrils more efficiently than nasal sprays. 
10.1.2Nasal sprays  
Both solution and suspension formulat ions can be 
formulated into nasal sprays. Due to the availability of 
metered dose pumps and actuators, a nasal spray can 
deliver an exact dose anywhere from 25 to 200 µL. The 
particle size and morphology (for suspensions) of the drug 
and viscosity of the formulation determine the choice of 
pump and actuator assembly. So lution and suspension 
sprays are preferred over powder sprays because powder 
results in mucosal irritation.
66
 
Nasal emulsions, microemulsions and nanoparticles 
Intranasal emulsions and nanoparticles have not been 
studied as extensively as other liquid nasal delivery  
systems. Nasal emulsions offer the advantages for local 
application mainly due to the viscosity. One of the major 
disadvantages is poor patient acceptability. The physical 
stability of emulsion formulations and precise delivery are 
some of the main formulation issues.  
10.2 SEMI-SOLID DOSAGE FORMS  
Semi-solid systems, for example gels, ointments and liquid 
systems containing polymers that gel at particular pH 
changes are usually employed for designing the nasal drug 
delivery systems. 
10.2.1Nasal gels 
Nasal gels are thickened solutions or suspensions, of high-
viscosity. The advantages of a nasal gel include the 
reduction of post-nasal dripping due to its high viscosity, 
reduction of the taste impact due to reduced swallowing, 
reduction of anterior leakage of the formulat ion, reduction 
of irritation by using soothing/emollient excipients, and 
target delivery to the mucosa for better absorption.
67
 
Vitamin B12 and apomorphine gel have been successfully 
employed to achieve desired therapeutic concentrations 
following nasal administration. 
10.3SOLID DOSAGE FORMS  
Solid dosage forms are also becoming popular for 
intranasal drug delivery, although these formulations are 
more suitable for pulmonary drug delivery and similar 
applications, since it can cover the vasculature within the 
epithelium of nasal mucosa. 
10.3.1Nasal powders   
Powder dosage forms may be developed if solution and 
suspension dosage forms cannot be developed, mainly due 
to lack of drug stability. The advantages of a nasal powder 
dosage form are the absence of preservative and superior 
stability of the drug in the formulat ion. However, the 
suitability of the powder formulation is dependent on the 
solubility, particle size, aerodynamic properties and nasal 
irritancy of the active drug and/or excip ients. An additional 
advantage of this system is local applicat ion of drug, but 
nasal mucosa irritancy and metered dose delivery are some 
of the challenges for formulation scientists and device 
manufacturers who are interested in powder dosage 
forms.
38 
11. APPLICATION OF NASAL DRUG DELIVERY 
SYSTEM 
11.1Delivery of Vaccines through Nasal Route  
Nasal delivery of vaccines has been reported to not only 
produce systemic immune response, but also local immune 
response in the nasal lining, providing additional barrier of 
protection. The majority of the invading pathogens enter 
the body via mucosal surfaces.
68
 Therefore, mucosal s ites 
have a potential as first line of defense against entering 
pathogens. Pathogens are filtered from the inspired air by 
compaction and mucociliary clearance. Nasal secretions 
are known to contain immunoglobulins (IgA, IgG,IgM, 
IgE), protective proteins such as complement as well as 
neutrophils and lymphocytes in the mucosa.
69
 
Delivering the vaccine to the nasal cavity itself stimulates 
the production of local secretory IgA antibodies as well as 
IgG, p roviding an additional first line o f defense system.
69
 
 Main reasons for explo iting the nasal route for 
vaccine delivery  
 The nasal passages are rich in lymphoid tissue. 
 Creat ion of both mucosal and systemic immune 
responses. 
 Low cost, patient compliance, non-in jectable,and 
safe.  
The feasibility of the nasal route for admin istering 
vaccines against plague, diphtheria tetanus ,
70 
influenza,
71
 
cholera,
72
 and HIV
73
  has already been tested for  inducing 
both mucosal and systemic immune response against the 
carried antigen. Read et al
74
 have prepared nasal influenza  
vaccine using chitosan. Nasal influenza vaccination may  
prove to be a good alternative to parenteral inject ion 
because of the enhancement of the mucosal immune 
response and the ease of vaccine administration. This study 
investigated the use of chitosan, a bioadhesive polymer, as 
a nasal delivery system with inactivated, subunit influenza 
vaccine. Nagamoto et al. 
75
 prepared a novel vaccine 
carrier particu late system (nano-particles and emulsions) 
with chitosan and had evaluated the effect of this system 
on the immune response for intranasal delivery. Chitosan 
nanoparticles (NP) and chitosan-coated emulsions (CC 
Emul) were prepared by improvement of the method 
previously reported and by modified ethanol inject ion 
methods, respectively. Jiang et al.
76
 prepared chitosan 
microspheres by ionic gelation process with sodium sulfate 
for nasal vaccine delivery. Bordetella Bronchiseptica 
Dermonecrotoxin (BBD) as a major virulence factor of a 
causative agent of atrophic rhinitis (AR) was loaded to the 
chitosan microspheres for vaccination. 
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Table 1: Nasal Drug Product for Vaccination Available in the Market
71, 74, 76
 
Vaccine (Product name) Dosage form Status Manufacturer 
Human influenza vaccine 
 (Nasalflu Berna)  
Virosomes (Spray) Marketed (withdrawn) Berna Biotech  
Equine influenza vaccine (Flu Avert)  Drops Marketed Heska 
Porcine Bordetella bronchiseptica vaccine\(Maxi/ 
Guard Nasal Vac) 
Drops Marketed AddisonBiological 
Laboratory 
Feline Bordetella bronchiseptica vaccine (Nobivac Bp) Suspension drops Marketed Intervet 
Human Streptococcus A vaccine (StrepAvax) Proteosomes (nanoparticulate) Phase 2 ID Biomedical 
Human influenza vaccine (FluINsuru) Proteosomes (nanoparticulate) Phase 2 ID Biomedical 
Human influenza vaccine Not indicated. Phase 1/2 West PS 
Human influenza vaccine (FluMist) Spray Marketed Medlmmune Inc.  
Feline trivalent vaccine against calici herpes-1and 
parvovirus 
Drops Marketed Heska 
 
11.2 Nose to Brain drug delivery system 
Delivery of drugs to the central nervous system (CNS) 
remains a challenge in the development of efficacious 
agents for central targets, mainly due to the impenetrable 
nature of the blood-brain barrier (BBB). The utility of the 
nasal route as a portal for preferential delivery of 
therapeutic agents is in the focus of scientists. The BBB 
limits substrate penetration based on several 
characteristics, including lipophilicity, molecu lar size and 
specificity for a variety of ATP-dependent transport 
systems.1 
At the beginning of the previous century the direct 
connection between the brain and the open air was 
discovered: the olfactory neurons. Injection of dyes in the 
ventricles of rabbits and monkeys showed that the 
cerebrospinal flu id (CSF) is drained via the olfactory 
neurons into the olfactory neurons, originating from the 
olfactory bulb, connect the brain with the nasal cavity by 
penetrating the cribriform plate, which brings the neurons 
into the nasal mucosa. This coined the idea that this 
transport route could also exist in the opposite direction, 
which would imply direct access from the nasal cavity to 
the brain, thus circumventing the BBB. This opened up a 
new perspective in the research field of drug targeting to 
the CNS, lymphatic vessels and the nasal mucosa.A 
growing numbers of recent reports have demonstrated the 
effectiveness of intranasal admin istration of 
neuroprotective agents in decreasing ischemic brain in jury. 
For example, Ying et al.
77
 recently reported that intranasal 
administration of NAD+ profoundly decreased brain injury 
in a rat model of t ransient focal ischemia.  
Similarly, Wei et al.
77
 showed that intranasal 
administration of the PARG inhibitor Gallo tannin 
decreased ischemic brain injury in rats. Such agents are 
believed to provide neuroprotection by diminishing or 
abolishing activation of poly (ADP-ribose) polymerase-1 
(PARP-1), which plays a significant role in ischemic brain  
damage. NAD+ was observed to reduce infarct format ion 
by up to 86% even when administered at 2 hours after 
ischemic onset.   
Recently, Shi et al.
78
 Investigated the extent of systemic 
absorption and uptake of meptazinol (MEP) hydro-
chloride in cerebrospinal fluid (CSF) after intranasal 
admini-stration on rats and compared with oral 
administration. CSF samples were collected by a serial 
sampling method. The concentration of MEP in the 
biological samples was measured by HPLC with 
fluorescence detector. A rapid and significant level of 
MEP in the plasma and CSF was achieved after nasal 
administration whereas the oral admin istration resulted in 
considerably lower drug concentrations. The area under 
curve (AUC) in plasma and CSF from the nasal route was 
7.375 and 15.6 fo lds compared with those of the oral route, 
respectively. The outcome of the research indicated that 
intranasal MEP is able to show quick absorption and 
improve the bioavailability, wh ich could be a promising 
alternative to oral administration..  
Chen et al.
79
 investigated the potential of delivering nerve 
growth factor to the brain along the olfactory neural 
pathway for the treatment of Alzheimer’s disease and 
found that the nerve growth factor reached the brain within 
an hour achieving the highest concentration in the 
olfactory bulb and less in other brain regions. Hui Yu et  
al.
80
 developed direct nose-to-brain delivery of a growth 
hormone releasing neuropeptide, hexarelin after intranasal 
administration to rabbits and investigate the olfactory 
transfer of a growth hormone releasing neuro-peptide, 
hexarelin to the brain tissues by comparing brain uptake 
levels after intranasal admin istration with those after 
intravenous administration.  Frey declared that by nasally 
administering insulin-like growth factor (IGF-1) the drug 
could bypass the blood   brain barrier and reach the central 
nervous system directly from the nasal cavity.
81
 
Tomotaka Sh ingakia et al.
82
 The transnasal delivery of 5-
fluorouracil to the rat brain is enhanced by acetazolamide 
and  evaluate the effect of acetazolamide (AZA), an  
inhibitor of the secretion  of cerebrospinal flu id (CSF), on 
the direct drug transport from the nasal cavity to the CSF 
and the brain uptake of a model d rug, 5-fluorouracil (5FU). 
Kao et al.
83
 studied the nasal transport of  various esters, 
such as butyl and methyl, of the carboxyl group of  L-dopa 
in the rat model and found significantly higher levels of L-
dopa in the CSF and the olfactory bulb than did equimolar 
doses given intravenously. 
Kumar et al.
84
 have studied the nasal uptake of tritium-
labeled estradiol and progesterone in rhesus monkeys. 
Both compounds were found to be absorbed intranasally 
and were able to penetrate into cerebrospinal fluid rap idly. 
A comparison of the plasma:CSF rat io of the two 
compounds indicated more steroids accumulated in the 
CSF after ability and minimizing variation. They 
demonstrated intranasal ad-ministration compared to the 
intravenous route. This result suggested that the two 
steroids can be absorbed from the nasal cavity and reach 
the brain directly via the respiratory and olfactory mucosa. 
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Sakane et al.
85
 reported that following intranasal ad-
ministration of the antibiotic cephalexin to rats, higher 
CSF concentration was reached at 15 min  but it declined to 
approximately half that concentration at 30 min . Because 
cephalexin do not cross the BBB well and CSF 
concentration was 166-fo ld higher after intranasal 
administration than after systemic administration in s pite 
of similar blood levels, it was concluded that cephalexin  
entered the CSF d irectly from the nasal cavity. Using a 
series of fluorescene inisothiocyanate-labeled dextrans 
(FITC-dextran) with increasing molecu lar weights, it was 
found that dextrans with molecular weights of upto 20,000 
daltons could be transported directly from the nasal cavity 
of rats into the CSF. The concentration of the FITC-
dextrans in the CSF increased with decreasing molecu lar 
weight. These FITC-dextrans were not found in the CSF 
after intravenous administration. 
Table 2: Drugs and drug-related compounds reported to reach the CNS after nasal administration in di fferent 
animal models 
Drug molecule Species Sample  Method References  
Adenoviral lacZ vector Hamster Mouse Brain  Histochemical 105 
Bupivacaine  Rat  CSF HPLC 106 
Cephalexin  Rat  CSF HPLC 85 
Chlorpheniramine  Rat  CSF HPLC 107 
Cocaine Rat  Brain tissue HPLC 108 
D4T Rat  CSF HPLC 109 
Dihydroergotamine Monkey Brain tissue Radioactivity counting 110 
Fibroblast growth factor Mouse CSF Motor activity,Dopamine activ ity 111 
Estradiol Rabbit  CSF Radioactivity counting 84 
Tetracaine Rat  CSF HPLC 105 
Hydroxyzine  Mouse CSF HPLC 112 
Insulin Rat  Brain tissue Radioactivity counting 113,114 
Lidocaine Rat  CSF HPLC 115 
Midazolam Dog CSF HPLC 116 
Monosialoganglioside Rat  CSF Immuno-enzymat ic assay 117 
Nerve growth factor Rat  Brain tissue  CSF ELISA, Radioactivity counting 79 
-Alanine (as carnosine) Hamster Mouse Brain tissue/CSF Autoradiography,Biochemical analysis  118 
 
11.3  Delivery of Peptide and Non-Peptide Drugs for 
Systemic Effect through Nasal Route  
Most peptides and proteins, being hydrophilic polar 
molecules of relatively high molecular weight, are poorly 
absorbed across biological membranes with bio-
availability obtained in the region of 1–2% concentrations 
when admin istered as simple solutions.
86
 This low uptake 
may be adequate for the development of some commercial 
products like  desmopressin and calcitonin because they 
have a wide therapeutic index. But for certain peptide 
drugs such as insulin which does not have the luxury of 
wide therapeutic index it is essential to develop the novel 
formulat ion strategies. 
In order to produce a product with a good bioavailability 
that can provide sufficient reliability in dosing and 
overcome these problems much research has been carried 
out in the areas of absorption enhancers and bioadhesive 
agents. Absorption enhancers are used to increase the 
bioavailability, and these enhancers are basically  
surfactants, glycosides, cyclodextrin and glycols. Recent 
studies have shown that the high bioavailability achieved 
with absorption enhancers for the delivery of polar 
compounds across mucosal membranes can be associated 
with t issue damage.
87
 Hence care should be taken that the 
absorption enhancer used should not only increase the 
bioavailability but should also be harmless to the nasal 
mucosa.  The classical example of a polypeptide 
compound with low nasal bioavailability is calcitonin. Its 
molecular weight is approximately 3,500 daltons and 
contains 32 amino acid in length. when calcitonin was 
given intranasally to rats and rabbits using a number of 
different cyclodextrins, its absorption when measured as 
decrease in serum calcium concentration, was found to be 
significant in comparison to the formulation without 
cyclodextrin addition.
88
 It has been observed that 
increasing the time of contact with the nasal mucosa can 
increase the nasal absorption of insulin. The clearance half 
life can be increased from 15 min  with nasal solution to 
240 min using starch microspheres (SMS).Insulin  
administered in combination with SMS resulted in 497% 
increase in AUC for p lasma insulin as compared to insulin 
solution. The AUC increased by 1657% compared to 
insulin solution when an enhancer lysophosphatidylcholine 
was used with insulin and SMS [70]. When a surfactant 
such as saponin, sodium g lycolate or BL-9 was added to 
the preparation, the absorption of insulin from the nasal 
mucosa was enhanced independent of pH.
89
 Absorption 
enhancing effect of different cyclodextrins  on intranasally 
administered insulin in rats and rabbits was determined. 
Dimethyl-beta-cyclodextrin   was found to be most 
potent.
90,91
 Nasal absorption is also promoted by medium 
chain fatty acid salt
92
 glycyrrhetinic acid derivatives in 
rat
93
 sodium-tauro-24, 25-d ihydrofusidate in sheep.
94
 Etr  
et al.
95
 demonstrated that the blood glucose remained low 
for 3 h after lunch when insulin was used intranasaly with 
1%  deoxycholate in type1 d iabetics. Other p roteins like 
luteinizing hormone releasing hormone,
96
 growth 
hormone
97
 and adreno-corticotrophic  hormone
98
 have 
been administered  intranasaly.
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Table 3: Nasal Drug Products (Proteins and Peptides) for Systemic Drug Delivery 
(2, 3, 6, 7)
 
Drug Substance  
(Product name 
Indication Dosage form Status  Manufacturer  
Salmon calcitonin (Karil 200 I.E.) Osteoporosis Solution (spray) Marketed Novartis Pharma 
Desmopressin (Minirin Nasenspray) Antidiuretic hormone Solution (spray) Marketed Ferring Arzneimitted 
Buserelin (Profact nasal) Prostate cancer Solution (spray) Marketed Aventis Pharma 
Nafarelin (Synarela) Endometriosis Solution (spray) Marketed Pharmacia  
Oxytocin (Syntocinon) Lactation induction Solution (spray) Marketed Novartis Pharma 
Protirelin (antepan*  nasal) (Relefact* 
TRH nasal) 
Thyroid diagnostics Solution (spray) Marketed Sanofi-synthelabo 
Aventis Pharma 
 
Table 4: Nasal Drug Products (Non-Peptide) for Systemic Drug Delivery on the Market 
(2, 3, 6, 7)
 
 
Unlike h igh molecular weight peptides, the small non-
peptide lipophilic drugs (MW below 1000) are better ab-
sorbed through the nasal mucosa even in the absence of 
ab-sorption enhancers. The underlying epithelium of the 
nasal membrane is highly vascularized and the nasal cavity 
has a large surface area readily accessible for drug 
absorption because of the presence of nasal turbinates. As 
a consequence, low molecular weight lipophilic drugs, 
such as propanolol,
 99 
progesterone
100
 are well absorbed 
across the nasal cavity and resulting in a faster onset of 
action.
86
 
Recently, Chavan et al.
101
 have tried to increase the nasal 
absorption of sumatriptan succinate by using bile salts. A 
rat  in situ nasal perfusion technique was used to examine 
the rate and extent of absorption of sumatriptan succinate. 
In vitro enzymatic drug degradation studies were carried  
out with rat nasal washings. Various experimental 
conditions such as nasal perfusion rate, pH of the perfusion 
medium and concentrations of absorption enhancers such 
as sodium deoxycholate, sodium caprate, sodium 
tauroglycocholate and EDTA were optimized.  In vivo 
studies were carried out for the optimized formulation in  
rabbits and the pharmacokinetics parameters of nasal 
solution were compared with marketed nasal solutions. 
Nasal absorption of sumatriptan succinate was pH 
dependent. It was found maximum at pH 5.5 and decreased 
at higher pH values. In in -vitro enzymat ic degradation 
studies, no measurable degradation was observed during 
the first week. The extent of drug absorption was increased 
by absorption enhancers. Sodium deoxycholate appeared 
to be more effective for enhancing the nasal absorption of 
sumatriptan succinate than the other absorption enhancers. 
the order of increasing absorption of sumatriptan succinate 
caused by the enhancers was sodium deoxycholate  >  
sodium caprate > sodium tauroglycocholate  > EDTA.  
Wermeling et al.
102
 have evaluated the efficacy and 
tolerability of a sterile, unpreserved butorphanol tartrate 
nasal spray administered via a unit-dose device in the 
treatment of moderate to severe pain after dental impaction 
surgery. In this study, sterile nasal spray of butorphanol 
tartrate administered via a unit -dose device provided 
effective post surgical analgesia in approximately half of 
patients who had under-gone surgery to remove impacted 
third molars. Intranasal route has also been tried with 
limited success for drugs such as steroids (corticosteroids, 
estradiol, testosterone, and so on),
 103, 104
 anti-hypertensives 
(nifed ipine, nitroglycerine, propranolol, hydralazine,), 
analgesics (buprenorphine, morphine), antibiotics and 
antivirals.
106-109
 
12. CONCLUS ION – 
Drug delivery through nasal route provides a practical, non 
invasive method of by passing the blood brain barrier 
(BBB) in order to deliver therapeutic agents to the brain. 
This method allows drugs that do not cross the BBB to be 
delivered to the central nervous system in a few minutes 
along with both the olfactory and trigeminal neuronal 
pathway. This delivery system has clinical benefits like 
reduction in drug dosage and systemic exposure, which  
results in lesser side effects. It is expected that nasal drug 
formulat ions will continue reach to the market and this 
delivery will include not only drugs for acute and chronic 
disease but also novel nasal vaccines for local or systemic 
protection against microbial infection. However it is well 
known that intranasal route has several limitations which 
must be overcome to develop a successful nas al 
formulat ion. Drug related factor and pathophysiological 
condition of nose determine the nasal drug absorption. 
Some common approaches, like increasing the nasal 
residence time of drug, use of absorption or penetration 
enhancers and min imization of the mucociliary clearance, 
enhances the bioavailability of nasally administered drug. 
This route is believed to be an alternative route to oral and 
parenteral because of the successful administration of 
vaccines and biomolecules such as proteins, peptides and 
non-peptide drugs, that are susceptible to enzymatic or 
acidic degradation and first-pass hepatic metabolis m 
.Moreover  it also offers noninvasiveness, self medication, 
patient comfort and patient compliance which are hurdled 
in intravenous drug therapy. 
 
Drug Substance  
(Product name 
Indication Dosage form Status  Manufacturer  
Zolmitriptan (AscoTop* Nasal Migraine  Solution (spray) Marketed Astra Zeneca 
Sumatriptan (Imigran* Nasal Migraine  Solution (spray) Marketed Glaxo SmithKline 
Dihyfroergotamin (Migranal* Nasal Spray  Migraine  Solution (spray) Marketed Novartis Pharma 
Estradiol (Aerodiol*) Hormone replacement Solution (spray) Marketed Servier 
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